Citadel Advisors’s Achieve Life Sciences ACHV Stock Holding History

Citadel Advisors’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,000	Closed	-$84.5K	–	12866
2025 Q4	$84.5K	Sell	17,000 -14,100	-45%	-$61.5K	﹤0.01%	11761
2025 Q3	$98K	Buy	31,100 +3,600	+13%	+$9.88K	﹤0.01%	11863
2025 Q2	$62.1K	Buy	27,500 +25,600	+1,347%	+$72.9K	﹤0.01%	11661
2025 Q1	$5.07K	Buy	1,900 +1,400	+280%	+$4.35K	﹤0.01%	13842
2024 Q4	$1.76K	Sell	500 -3,200	-86%	-$14.5K	﹤0.01%	14151
2024 Q3	$17.5K	Sell	3,700 -900	-20%	-$4.11K	﹤0.01%	12880
2024 Q2	$21.6K	Sell	4,600 -2,100	-31%	-$10.1K	﹤0.01%	12560
2024 Q1	$30.5K	Buy	+6,700	New	+$29.7K	﹤0.01%	12687
2023 Q4	–	Sell	-21,700	Closed	-$93.3K	–	14169
2023 Q3	$93.3K	Buy	21,700 +7,200	+50%	+$36.3K	﹤0.01%	10988
2023 Q2	$75.3K	Buy	14,500 +10,500	+263%	+$73.6K	﹤0.01%	11308
2023 Q1	$27.2K	Buy	4,000 +1,000	+33%	+$4.75K	﹤0.01%	12822
2022 Q4	$7.41K	Buy	+3,000	New	+$7.7K	﹤0.01%	13825

Other funds holding ACHV

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's ACHV Position: Q3 2025 in Review

Citadel Advisors sold out of Achieve Life Sciences (ACHV) in Q3 2025, closing a stake of 24,718 shares — an estimated $67.8K sold.

Citadel Advisors first reported a position in ACHV in Q1 2015 and held it in 22 quarters. The position peaked at $149K in Q4 2021. 66 funds tracked by Wall St. Rank hold ACHV as of Q3 2025.

Citadel Advisors reported no remaining Achieve Life Sciences position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 24,718 Achieve Life Sciences shares in Q3 2025, an estimated $67.8K.
Citadel Advisors first reported a position in Achieve Life Sciences in Q1 2015 and held it in 22 quarters.
Citadel Advisors's Achieve Life Sciences position peaked at $149K in Q4 2021.
66 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.